Investor Relations Contact:Barbara RyanEmail: email@example.comPhone: 203-274-2825Media Contact:Lori GorskiEmail: firstname.lastname@example.orgPhone: 617-551-4096
WALTHAM, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 5:00 pm PT at the Encore at the Wynn, Las Vegas, NV. The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay of the presentation will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation. About Radius Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.